Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Trial details
- Registry ID
- NCT07621718
- Phase
- Phase 3
The FDA approved Oxaliplatin on 9 Aug 2002.
Drug identity checked against registry records
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2002-08-09Day | Oxaliplatin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021492", "applicant_as_listed_by_fda": "SANOFI AVENTIS US", "brand_names": ["ELOXATIN"], "active_ingredients": ["OXALIPLATIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20020809", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |